Limb Differences in the Therapeutic Effects of Complex Decongestive Therapy on Edema, Quality of Life, and Satisfaction in Lymphedema Patients

Abstract Background: The aim of this study was to evaluate the effects of complex decongestive therapy (CDT) in patients with breast cancer-related lymphedema (BCRL), in regard to volume reduction, functional status and quality of life (QoL).Methods: Fifty patients with unilateral BCRL were included. The demographic variables focusing on lymphedema were recorded. All patients received combined phase 1 CDT including skin care, manual lymphatic drainage, multilayer bandaging and supervised exercises, five times a week for three weeks, as a total of 15 sessions. Patients were assessed by limb volumes and excess volumes according to geometric approximation derived from serial circumference-measurements of the limb, prior and at the end of third week. The functional disability was evaluated by quick disability of arm, shoulder and hand questionnaire (DASH). Quality of life was assessed by the European Organization forResearch and Treatment of Cancer Core Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) and its breast cancer module (EORTC-QLQ-BR23).Results: Fifty females with mean age of 53.22±11.2 years were included. The median duration of lymphedema was 12 months. There were 22 patients in stage1, 26 in stage2 and 2 patients in stage3. The mean baseline limb and excess volumes were significantly decreased at the end of therapies (3262±753cm³ vs 2943±646.6cm³ and 31.36±16.5% vs 19.12±10.4%, p=0.000,respectively). The DASH and EORTC-QLQ-C30 and BR23 scores were also decreased significantly (p<0.05). The improvements in volumes were related negatively with the duration of lymphedema,and the stage of lymphedema. Conclusion: In conclusion phase 1CDT in a combined manner performed daily for 3 weeks, greatly reduces the volumes as well as improves the disability and QoL, especially when performed earlier.

Download Full-text

Combıned-Complex Decongestıve Therapy Reduces Volume And Improves Quality Of Lıfe And Functıonal Status In Patıents Wıth Breast Cancer-Related Lymphedema

10.21203/rs.3.rs-20955/v2 ◽

2020 ◽

Author(s):

Pinar Borman ◽

Aysegul Yaman ◽

Sina Yasrebi ◽

Adeviye Pinar Inanli

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Functional Status ◽

Excess Volumes ◽

Complex Decongestive Therapy ◽

Eortc Qlq C30 ◽

Breast Cancer Related Lymphedema ◽

Eortc Qlq ◽

Decongestive Therapy

Abstract Background: The aim of this study was to evaluate the effects of complex decongestive therapy (CDT) in patients with breast cancer-related lymphedema (BCRL), in regard to volume reduction, functional status and quality of life (QoL).Methods: Fifty patients with unilateral BCRL were included. The demographic variables focusing on lymphedema were recorded. All patients received combined phase 1 CDT including skin-care, manual lymphatic drainage, multilayer bandaging and supervised exercises, five times a week for three weeks, as a total of 15 sessions. Patients were assessed by limb volumes and excess volumes according to geometric approximation derived from serial circumference-measurements of the limb, prior and at the end of third week. The functional disability was evaluated by quick disability of arm, shoulder and hand questionnaire (DASH). Quality of life was assessed by the European Organization for Research and Treatment of Cancer Core Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) and its breast cancer module (EORTC-QLQ-BR23).Results: Fifty females with mean age of 53.22±11.2 years were included. The median duration of lymphedema was 12 months. There were 22 patients in stage1, 26 in stage2 and 2 patients in stage3. The mean baseline limb and excess volumes were significantly decreased at the end of therapies (3262±753cm³ vs 2943±646.6cm³ and 31.36±16.5% vs 19.12±10.4%, p=0.000,respectively). The DASH and EORTC-QLQ-C30 and BR23 scores were also decreased significantly (p<0.05). The improvements in volumes were related negatively with the duration of lymphedema,and the stage of lymphedema. Conclusion: In conclusion phase 1CDT in a combined manner performed daily for 3 weeks, greatly reduces the volumes as well as improves the disability and QoL, especially when performed earlier.Trial Registration: 'retrospectively registered’

Download Full-text

The Reduction in Upper Extremity Volume and Improved Quality of Life in Women With Post-Mastectomy Lymphedema by Complex Decongestive Therapy

Women’s Health Bulletin ◽

10.17795/whb-29324 ◽

2016 ◽

Vol 3 (2) ◽

Author(s):

Negin Hadi ◽

Esmaeel Shabaninezhad ◽

Zahra Shabgard Shahraki ◽

Ali Montazeri ◽

Sedigheh Tahmasebi ◽

...

Keyword(s):

Quality Of Life ◽

Upper Extremity ◽

Complex Decongestive Therapy ◽

Decongestive Therapy

Download Full-text

Effects of complex decongestive therapy on quality of life, depression, neuropathic pain, and fatigue in women with breast cancer-related lymphedema

Turkish Journal of Physical Medicine and Rehabilitation ◽

10.5606/tftrd.2017.779 ◽

2017 ◽

Vol 63 (4) ◽

pp. 329-334 ◽

Cited By ~ 4

Author(s):

Hilal Yesil

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Neuropathic Pain ◽

Complex Decongestive Therapy ◽

Breast Cancer Related Lymphedema ◽

Decongestive Therapy

Download Full-text

Ketamine-Assisted and Culturally Attuned Trauma Informed Psychotherapy as Adjunct to Traditional Indigenous Healing: Effecting Cultural Collaboration in Canadian Mental Health Care

Behavioral Sciences ◽

10.3390/bs11090118 ◽

2021 ◽

Vol 11 (9) ◽

pp. 118

Author(s):

Sherry-Anne Muscat ◽

Geralyn Dorothy Wright ◽

Kristy Bergeron ◽

Kevin W. Morin ◽

Courtenay Richards Crouch ◽

...

Keyword(s):

Quality Of Life ◽

Mental Health ◽

Treatment Effectiveness ◽

Indigenous Health ◽

Indigenous Communities ◽

Therapeutic Effects ◽

Behavioral Systems ◽

Health And Wellbeing ◽

Trauma Informed

Ketamine therapy with culturally attuned trauma-informed psychotherapy in a collaborative cross-cultural partnership may provide a critical step in the operationalization and optimization of treatment effectiveness in diverse populations and may provide a foundation for an improved quality of life for Indigenous people. Decolonizing Indigenous health and wellbeing is long overdue, requiring an equal partnership between government and Indigenous communities, built upon an aboriginal culture holistic foundation of balance of mind, body, social and spiritual realms, and within the context of historical and lived experiences of colonialism. Culturally attuned trauma-informed psychotherapy paired with ketamine—a fast-acting antidepressant that typically takes effect within 4 hours, even in cases of acute suicidality—may be uniquely qualified to integrate into an Indigenous based health system, since ketamine’s therapeutic effects engage multiple neuropsychological, physiological, biological, and behavioral systems damaged by intergenerational complex developmental trauma. Ketamine holds the potential to serve as a core treatment modality around which culturally engaged treatment approaches might be organized since its brief alteration of normal waking consciousness is already a familiar and intrinsic element of healing culture in many Indigenous societies. There is great need and desire in Indigenous communities for respectful and sacred partnership in fostering more effective mental health outcomes and improved quality of life.

Download Full-text

Non-hormonal treatment for genitourinary syndrome of menopause

Voprosy ginekologii akušerstva i perinatologii ◽

10.20953/1726-1678-2021-2-141-146 ◽

2021 ◽

Vol 20 (2) ◽

pp. 141-146

Author(s):

N.A. Tatarova ◽

◽

V.A. Linde ◽

S.N. Gusev ◽

◽

...

Keyword(s):

Quality Of Life ◽

Hormonal Treatment ◽

Therapeutic Effects ◽

Life Questionnaire ◽

Genitourinary Syndrome Of Menopause ◽

Quality Of Life Questionnaire ◽

Vulvovaginal Atrophy ◽

Positive Effects ◽

Genitourinary Syndrome

The genitourinary syndrome of menopause (GSM) is due to the development of atrophic and dystrophic processes in estrogendependent tissues and structures of the lower third of urinary tract in different periods of aging of the reproductive system. Nonhormonal treatment for GSM is considered as a first-line treatment and includes the use of gels, creams and suppositories that contribute to the restoration of hydrolipid balance, stimulating the collagen production that have an anti-inflammatory, antiseptic, regenerating effect, as well as increasing mucosal resistance and reducing the risk of adhesion of conditionally pathogenic infection. Objective. To evaluate the effectiveness, safety and acceptability of the vaginal cream for intimate hygiene EstrogialTM Plus in women with symptoms of vulvovaginal atrophy (VVA) and GSM. Patients and methods. 24 women aged 43 to 58 were examined. The inclusion criteria were the symptoms of GSM and VVA, the vaginal health index – no more than 20 points. During the course of the study, four visits were carried out, including standard observational procedures, filling the Quality of Life Questionnaire, the administration of treatment. The application of the cream Estrogial™ Plus in doses was prescribed 1 time per day on the vulvar vestibule for 30 days. The effectiveness of therapy was evaluated, all patients continued therapy for up to 60 days. According to the modified questionnaire for general clinical assessment, the state «very much improved» was revealed in 83.3% of patients with a severe form of GSM and VVA and in 66.7% with moderate VVA, «much improved» – in the rest. After treatment, 52% of patients had no symptoms of VVA, and 48% had symptoms in a mild form. Filling the Menopause-Specific Quality of Life Questionnaire (MENQOL), all 24 patients reported positive effects in the form of increased libido and reduced vaginal dryness during sexual intercourses. The study presents clinical cases of cured patients with GSM and VVA. Conclusion. The data obtained during the study make it possible to conclude that the intravaginal administration of the cream EstrogialTM Plus in doses is effective for the treatment of GSM and VVA. The proven therapeutic effects and safety of the use of local non-hormonal treatment enhance the prospects for providing treatment and preventive care for women during the menopausal transition and menopause. Key words: vulvovaginal atrophy, genitourinary syndrome of menopause, non-hormonal treatment, Estrogial™ Plus

Download Full-text

The prophylactic and therapeutic effects of moxibustion combined with traditional Chinese medicine decoction for treating chemotherapy-induced myelosuppression in early-stage breast cancer: study protocol for a randomized controlled trial

Trials ◽

10.1186/s13063-020-04749-6 ◽

2020 ◽

Vol 21 (1) ◽

Cited By ~ 1

Author(s):

Yajie Ji ◽

Siyu Li ◽

Xinyue Zhang ◽

Yu Liu ◽

Qing Lu ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Chemotherapy Regimen ◽

Early Stage ◽

Controlled Trial ◽

Early Stage Breast Cancer ◽

Therapeutic Effects ◽

Breast Cancer Patients ◽

Randomized Controlled

Abstract Background Traditional Chinese medicine (TCM) has a long history of use in breast cancer, but lacking systematic evidence to support its clinical benefits. In this study, we evaluated the prophylactic and therapeutic effects of moxibustion combined with decoctions for treating chemotherapy-induced myelosuppression (CIM) in early-stage breast cancer patients. Methods This is a randomized controlled clinical trial single-blinded for TCM decoction but not moxibustion. Patients are equally divided into the control group without decoction and moxibustion treatment (control), the decoction+moxibustion group (MD), and the placebo+moxibustion group (MP), according to the following stratification factors: age (below 40s, 40s, 50s, and 60s or above), chemotherapy regimen (anthracyclines, taxanes, anthracyclines+taxane, and others), and chemotherapy strategy (adjuvant and neoadjuvant). The TCM decoction is Wenshen Shengbai Decoction. The anticipated sample size is 462 cases (154 cases in each group). All participants are expected to treat with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF). The primary outcomes include the proportion of patients with relief of leukopenia and/or neutropenia, the myelosuppression-associated serious adverse event including grade 3–4 leukopenia and/or neutropenia, and febrile neutropenia, and the dose of rhG-CSF. The secondary outcomes include chemotherapy adherence, stratified analysis, adverse reactions, quality of life by EORTC Breast-Cancer-Specific Quality of Life Questionnaire including EORTC QLQ-C30 (V3.0) and QLQ-BR23, TCM Constitution, and 3-year disease-free survival and overall survival. Baseline information including age, surgical approach, chemotherapy regimen and strategy, pathological stage, and molecular subtype will be recorded. Discussion This will be the first randomized controlled trial to evaluate the efficacy of moxibustion combined with TCM decoction in treating CIM in early-stage breast cancer patients, aiming to standardize the TCM decoction and moxibustion method, thus providing evidence for its clinical benefit. Trial registration chictr.org.cn ChiCTR-INR-16009557. Registered on 23 October 2016.

Download Full-text

Study of quality of life in the patients with personality neurotic development

Journal of New Medical Technologies eJournal ◽

10.12737/6445 ◽

2014 ◽

Vol 8 (1) ◽

pp. 0-0

Author(s):

Бочкарева ◽

N. Bochkareva ◽

Кирюхина ◽

S. Kiryukhina ◽

Подсеваткин ◽

...

Keyword(s):

Quality Of Life ◽

Social Relations ◽

Social Inclusion ◽

Hyperbaric Oxygenation ◽

Psychiatric Symptoms ◽

Personality Development ◽

Social Activity ◽

Performance Criteria ◽

Therapeutic Effects

Objective: To study the therapeutic effects of mexidol, hyperbaric oxygenation and timogena in complex treatment of patients with neurotic personality development and its impact on quality of life of patients. Material and methods: The study included 142 patients with neurotic personality development. Patients of the first group were prescribed conventional therapy anxiolytic and antidepressant within 30 days. Patients of the second group were treated basic therapy and antioxidant immune correctors, sessions of hyperbaric oxygenation. Performance criteria for the final evaluation of the results of treatment were: reduction of the severity of psychiatric symptoms, improve mental and physical performance and social activity. Results: In patients with neurotic personality development identified physical and mental exhaustion, re-duced intentions, low productivity at work and social exclusion, which is reflected in low rates of quality of life in social relations and in the psychological realm. These symptoms on a background of traditional anxiolytic and antidepressant therapy didn’t cropped, but compounded undesirable actions of these drugs. Combined anxiolytic and antidepressant combination with hyperbaric oxygenation and antioxidant immune correctors demonstrate the effectiveness of the therapeutic effects of metabolic therapy, which is manifested in a significant improvement in physical, mental and social functioning of patients and improve their quality of life. Conclusions: The combination of paroxetine and diazepam with mexidol, hyperbaric oxygenation therapy, timogena can reduce the undesirable effects of antidepressants and benzodiazepine anxiolytics, increase efficiency of patients, their activity in communication, social inclusion and quality of life, indicating that the high efficacy and safety of this regimen.

Download Full-text

Therapeutic Effects of Intra-Articular Botulinum Neurotoxin Versus Physical Therapy in Knee Osteoarthritis

Anesthesiology and Pain Medicine ◽

10.5812/aapm.112789 ◽

2021 ◽

Vol 11 (3) ◽

Author(s):

Zahra Rezasoltani ◽

Afsaneh Dadarkhah ◽

Seyed Morteza Tabatabaee ◽

Fateme Abdorrazaghi ◽

Morteza Kazempour Mofrad ◽

...

Keyword(s):

Quality Of Life ◽

Physical Therapy ◽

Knee Osteoarthritis ◽

Botulinum Neurotoxin ◽

Demographic Data ◽

Therapeutic Effects ◽

Vas Score ◽

Chronic Knee Pain ◽

Significant Difference

Background: Knee osteoarthritis (KOA) is the most common cause of chronic knee pain, and disability and different modalities have been used to improve pain and function. Botulinum toxin intra-articular injection is proposed to manage resistant joint pains. Objectives: This study was carried out to compare therapeutic effects of intra-articular botulinum neurotoxin (BTX) versus physical therapy (PT) in KOA. Methods: In this single-blind randomized clinical trial, patients with KOA attending to Imam-Reza Hospital, Tehran, Iran, from June 2018 to March 2019 were enrolled. Patients who met the inclusion criteria were randomly divided into BTX receiving a single intra-articular dose of 100 units (250 units from disport brand) and PT groups. The study was described for patients, and informed consent forms were received. For assessment of the pain and related severity, the VAS score and KOOS scales were used. Post-intervention assessment was done 1, 3, and 6 months after the intervention. The level of significance was set at α = 0.05. All data analyses were performed with SPSS version 26 for windows. Results: In this study, 50 patients were randomly divided into BTX and PT groups. All patients completed the study, and there was no loss to follow-up. There was no significant difference between demographic data of the two groups, including age and BMI. The VAS score was similar in the two groups at the beginning. KOOS subscales were not significantly different, but the quality of life was better in the BTX than the PT group (86.2 ± 15 vs. 72.1 ± 11.5, P < 0.001). One month after the intervention, all KOOS subscales were improved in the BTX group in comparison to the PT group (P < 0.001). This difference was statistically significant in the 3rd (P < 0.001 in all comparisons except Sport/Rec subscale in which P = 0.02) and 6th months (P < 0.001) after the intervention, and the improvement in all KOOS subscales and VAS score were higher in the BTX group than the PT group. The trend of KOOS subscales and VAS score was improved over time in the BTX (P < 0.001 in all tests), but the PT group showed no improvement (P > 0.05) except for Sport/Rec and VAS score (P < 0.001). Conclusions: Totally, it is concluded that the use of BTX can reduce pain and improve the function and quality of life in patients with KOA.

Download Full-text